Demethyleneberberine

Cat. No.: HY-N0592: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Demethyleneberberine is a blood-brain barrier-permeable antioxidant. Demethyleneberberine exerts antioxidant effects by targeting mitochondria, activates the AMPK signaling pathway to regulate lipid metabolism, and inhibits inflammation-related pathways such as NF-κB and MAPK. Demethyleneberberine can be used in the research of inflammatory and other diseases.

It is advisable to consider the salt form (Demethyleneberberine chloride) that retains the same biological activity.

For research use only. We do not sell to patients.

Demethyleneberberine Chemical Structure

CAS No. : 25459-91-0

Size	Price	Stock
5 mg		Ask For Quote & Lead Time
10 mg		Ask For Quote & Lead Time
25 mg		Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Demethyleneberberine:

Demethyleneberberine chloride

Other Forms of Demethyleneberberine:

Demethyleneberberine chloride In-stock

3 Publications Citing Use of MCE Demethyleneberberine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All NF-κB Isoform Specific Products:

View All Isoforms

NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All AMPK Isoform Specific Products:

View All Isoforms

NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

View All p38 MAPK Isoform Specific Products:

View All Isoforms

p38 MAPK Akt1 p38α p38β MAPK13 p38δ p38γ

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Demethyleneberberine (50 μM; 2 h) neutralizes 55% of H₂O₂-induced ROS in HepG2 cells^[1].
Demethyleneberberine (50 μM; 1 week) reverses ethanol-induced mitochondrial membrane potential depolarization in ethanol-exposed HepG2 cells^[1].
Demethyleneberberine (0-50 μM; 0-24 h) shows no toxicity to HepG2 cells at concentrations up to 50 μM, reduces cellular lipid accumulation by 25% at 10 μM, and activates the AMPK pathway in a dose- and time-dependent manner^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parmacokinetics

Species	Dose	Route	AUC_0-t	AUC_0-∞	C_max	T_max	T_1/2	MRT_0-∞	Bioavailability
Rat^[3]	2 mg/kg	i.v.	111.13 ng·h/mL	158.75 ng·h/mL	128.24 ng/mL	0.08 h	5.57 h	5.13 h	/
Rat^[3]	20 mg/kg	i.v.	27.14 ng·h/mL	29.83 ng·h/mL	60.22 ng/mL	0.08 h	4.26 h	4.13 h	2.44 %
Rat^[3]	40 mg/kg	i.g.	131.60 ng·h/mL	133.36 ng·h/mL	308.25 ng/mL	0.08 h	3.14 h	1.13 h	5.92 %
Mice^[3]	2 mg/kg	i.v.	226.16 ng·h/mL	343.51 ng·h/mL	94.50 ng/mL	0.08 h	6.80 h	10.54 h	/
Mice^[3]	40 mg/kg	i.g.	202.26 ng·h/mL	264.61 ng·h/mL	177.15 ng/mL	0.08 h	4.10 h	5.29 h	4.47 %

In Vivo

Demethyleneberberine (40 mg/kg; i.p.; 1 hour after each ethanol exposure; 3 exposures total) protects liver mitochondria of ICR mice against oxidative stress damage and ameliorates their acute alcoholic liver injury^[1].
Demethyleneberberine (40 mg/kg per day; i.p.; daily; 5 weeks) prevents chronic alcohol intake-induced liver injury and steatosis in ICR mice by inhibiting oxidative stress pathways and restoring fatty acid oxidation^[1].
Demethyleneberberine (20-40 mg/kg; i.p.; daily administration; for 4 consecutive weeks) alleviates MCD-induced non-alcoholic fatty liver disease (NAFLD) in ICR mice and spontaneous NAFLD in db/db mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	ICR mice (male, 8 weeks old, 24-26 g, acute alcoholic liver injury model)^[1]
Dosage:	40 mg/kg
Administration:	i.p.; 1 hour after each ethanol exposure; 3 exposures total
Result:	Attenuated ethanol-induced microsteatosis, swelling, and apoptosis in liver cells. Blunted elevated serum ALT levels. Blocked ethanol-induced 33% decline in mitochondrial GSH and GPx activity and 250% elevation in mitochondrial TBARS formation. Alleviated ethanol-mediated mitochondrial swelling. Significantly recovered ethanol-reduced mitochondrial AST activity by 50%. Ameliorated ethanol-induced mitochondrial ultrastructural damages and reduced lipid droplet accumulation.

Animal Model:	C57BLKS/J-Leprdb/Leprdb (db/db) mice (8-week-old male; spontaneous NAFLD model due to leptin deficiency)^[2]
Dosage:	20 mg/kg
Administration:	i.p.; daily; 4 weeks
Result:	Reduced liver/body index. Decreased hepatic TG and TC levels and improved liver function (reduced serum ALT). Decreased hepatic MDA. Reduced lipid droplet accumulation. Activated AMPK phosphorylation and increased phosphorylation of ACC. Reduced expression of lipogenic genes and inflammatory genes (IL-1β, TNFα). Increased expression of fatty acid β-oxidation genes (ACO, MCAD, CPT1A) and lipid transport genes (MTTP, ApoB).

Molecular Weight

324.35

Formula

C₁₉H₁₈NO₄⁺

CAS No.

25459-91-0

Appearance

Solid

Color

Light yellow to yellow

SMILES

COC1=C(OC)C2=C[N+]3=C(C4=CC(O)=C(O)C=C4CC3)C=C2C=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (30.83 mM; ultrasonic and adjust pH to 8 with HCl; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.0831 mL	15.4154 mL	30.8309 mL
5 mM	0.6166 mL	3.0831 mL	6.1662 mL
10 mM	0.3083 mL	1.5415 mL	3.0831 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (280 KB) SDS (251 KB)

COA (249 KB)

Handling Instructions (2659 KB)

References

[1]. Zhang P, et al. Demethyleneberberine, a natural mitochondria-targeted antioxidant, inhibits mitochondrial dysfunction, oxidative stress, and steatosis in alcoholic liver disease mouse model. J Pharmacol Exp Ther. 2015;352(1):139-147. [Content Brief]

[2]. Qiang X, et al. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress. Biochem Biophys Res Commun. 2016 Apr 15;472(4):603-9. [Content Brief]

[3]. Li J, et al. Pharmacokinetics, Tissue Distribution and Excretion of Demethyleneberberine, a Metabolite of Berberine, in Rats and Mice. Molecules. 2023;28(23):7725. Published 2023 Nov 23. [Content Brief]

[4]. Saklani P, et al. Demethyleneberberine, a potential therapeutic agent in neurodegenerative disorders: a proposed mechanistic insight. Mol Biol Rep. 2022;49(10):10101-10113. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.0831 mL	15.4154 mL	30.8309 mL	77.0772 mL
	5 mM	0.6166 mL	3.0831 mL	6.1662 mL	15.4154 mL
	10 mM	0.3083 mL	1.5415 mL	3.0831 mL	7.7077 mL
	15 mM	0.2055 mL	1.0277 mL	2.0554 mL	5.1385 mL
	20 mM	0.1542 mL	0.7708 mL	1.5415 mL	3.8539 mL
	25 mM	0.1233 mL	0.6166 mL	1.2332 mL	3.0831 mL
	30 mM	0.1028 mL	0.5138 mL	1.0277 mL	2.5692 mL